A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs), including crizotinib, are effective treatments in preclinical models and in cancer patients with ALK-translocated cancers. However, their efficacy will ultimately be limited by the development of acquired drug resistance. Here we re...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sasaki, Takaaki, Koivunen, Jussi, Ogino, Atsuko, Yanagita, Masahiko, Nikiforow, Sarah, Zheng, Wei, Lathan, Christopher, Marcoux, J. Paul, Du, Jinyan, Okuda, Katsuhiro, Capelletti, Marzia, Shimamura, Takeshi, Ercan, Dalia, Stumpfova, Magda, Xiao, Yun, Weremowicz, Stanislawa, Butaney, Mohit, Heon, Stephanie, Wilner, Keith, Christensen, James G., Eck, Michel J., Wong, Kwok-Kin, Lindeman, Neal, Gray, Nathanael S., Rodig, Scott J., Jänne, Pasi A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2011
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3278914/
https://ncbi.nlm.nih.gov/pubmed/21791641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-11-1340
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares